Briakinumab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | IL-12 and IL-23 |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| CAS Number | 339308-60-0 |
| ATC code | none |
Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Like ustekinumab, it targets the interleukins 12 and 23.[1]
As of November 2009[update], Phase III clinical trials for plaque psoriasis[2][3] and a Phase II trial for multiple sclerosis[4] have been completed, and a Phase II trial for Crohn's disease is underway.[5]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
- ↑ Lima, X. T.; Abuabara, K.; Kimball, A. B.; Lima, H. C. (2009). "Briakinumab". Expert Opinion on Biological Therapy. 9 (8): 1107. doi:10.1517/14712590903092188. PMID 19569977.
- ↑ ClinicalTrials.gov NCT00570986 A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- ↑ ClinicalTrials.gov NCT00691964 Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- ↑ ClinicalTrials.gov NCT00086671 Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
- ↑ ClinicalTrials.gov NCT00562887 Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
Categories:
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from November 2009
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs
